HER2 overexpression renders human breast cancers sensitive to PARP inhibition independently of any defect in homologous recombination DNA repair

Cancer Research

Volumn 72, Issue 18, 2012, Pages 4796-4806

  Nowsheen, Somaira ^a   Cooper, Tiffiny ^a   Bonner, James A ^a   LoBuglio, Albert F ^b   Yang, Eddy S ^a,b,c  

^a The University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZD 221; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; I KAPPA B ALPHA; INIPARIB; LAPATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; OLAPARIB; PROGESTERONE RECEPTOR; PROTEIN P53; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VELIPARIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER RESISTANCE; CELL VIABILITY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG SENSITIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE; GENE OVEREXPRESSION; HER2 GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECOMBINATION REPAIR; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; HUMANS; IMMUNOBLOTTING; POLY(ADP-RIBOSE) POLYMERASES; RECEPTOR, ERBB-2; RECOMBINATIONAL DNA REPAIR; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84866391539     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-1287     Document Type: Article

References (46)

1. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Xia W, Bacus S, Husain I, Liu L, Zhao S, Liu Z, et al. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA. Mol Cancer Ther 2010;9:292-9.
3. Merkhofer EC, Cogswell P, Baldwin AS. Her2 activates NF-κB and induces invasion through the canonical pathway involving IKKk. Oncogene 2009;29:1238-48.
4. Cao Y, Luo JL, Karin M. IkappaB kinase alpha kinase activity is required for self-renewal of ErbB2/Her2-transformedmammary tumor-initiating cells. Proc Natl Acad Sci U S A 2007;104:15852-7.
5. Stilmann M, Hinz M, Arslan S -C, Zimmer A, Schreiber V, Scheidereit C. A nuclear poly(ADP-Ribose)-dependent signalosome confers DNA damage-induced IkB kinase activation. Mol Cell 2009;36: 365 - 78.
6. Veuger SJ, Hunter JE, Durkacz BW. Ionizing radiation-induced NF-kB activation requires PARP-1 function to confer radioresistance. Oncogene 2009;28:832-42.
7. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
8. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell- McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
9. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235- 44.
10. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor- HER2/neu cross-talk in ER/HER2 positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
11. Benz CC, Scott GK, Sarup JC, Johnson RM, Tripathy D, Coronado E, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 1992;24:85-95.
12. Li L, Wang H, Yang ES, Arteaga CL, Xia F. Erlotinib attenuates homologous recombinational repair of chromosomal breaks in human breast cancer cells. Cancer Res 2008;68:9141-6.
13. Nowsheen S, Bonner JA, LoBuglio AF, Trummell H, Whitley AC, Dobelbower MC, et al. Cetuximab augments cytotoxicity with poly (ADP-Ribose) polymerase inhibition in head and neck cancer. PLoS One 2011;6:e24148.
14. Nowsheen S, Bonner JA, Yang ES. The poly(ADP-Ribose) polymerase inhibitor ABT-888 reduces radiation-induced nuclear EGFR and augments head and neck tumor response to radiotherapy. Radiother Oncol 2011;99:331-8.
15. Yang ES, Wang H, Jiang G, Nowsheen S, Fu A, Hallahan DE, et al. Lithium-mediated protection of hippocampal cells involves enhancement of DNA-PK dependent repair in mice. J Clin Invest 2009;119: 1124- 35.
16. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006;10:515-27.
17. Bai P, Canto C, Oudart H, Brunyunszki A, Cen Y, Thomas C, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011;13:461- 8.
18. Patel AG, De Lorenzo S, Flatten K, Poirier G, Kaufmann SH. Failure of iniparib to inhibit poly(ADP-ribose) polymerase in vitro. Clin Cancer Res 2012;18:1655-62.
19. Liu X, Shi Y, Maag DX, Palma JP, Patterson MJ, Ellis PA, et al. Iniparib nonselectively modi fies cysteine-containing proteins in tumor cells and is not a bona fi dePARPinhibitor. Clin Cancer Res 2012;18:510-23.
20. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specifi c killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005;434:913-7.
21. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS, Glazer PM. Inhibition of poly(ADP-ribose) polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad SciU S A 2010;107:2201-6.
22. Farmer H, McCabe N, Lord CJ, Tutt ANJ, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
23. Makino K, Day CP, Wang SC, Li YM, Hung MC. Upregulation of IKKalpha/IKKbeta by integrin-linked kinase is required for HER2/ neu-induced NF-kappaB antiapoptotic pathway. Oncogene 2004; 23:3883-7.
24. Cao N, Li S, Wang Z, Ahmed KM, Degnan ME, Fan M, et al. NF-kappaB- mediated HER2 overexpression in radiation-adaptive resistance. Radiat Res 2009;171:9-21.
25. La Rosa FA, Pierce JW, Sonenshein GE. Differential regulation of the cmyc oncogene promoter by the NF-kappa B rel family of transcription factors. Mol Cell Biol 1994;14:1039-44.
26. O'Shaughnessy J, Schwartzberg L, Danso M, Rugo H, Miller K, Yardley D, et al. A randomized phase III study of iniparib (BSI-201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC). J Clin Oncol 2011;29 (suppl; abstr 1007).
27. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, et al. Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 2009;15:1241-9.
28. Plummer R, Jones C,Middleton M,Wilson R, Evans J, Olsen A, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res 2008;14:7917 -23.
29. Mendes-Pereira AM, Martin SA, Brough R, McCarthy A, Taylor JR, Kim J-S, et al. Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors. EMBO Mol Med 2009;1:315-22.
30. van Vuurden DG, Hulleman E, Meijer OL, Wedekind LE, Kool M, Witt H, et al. PARP inhibition sensitizes childhood high grade glioma, medulloblastoma, and ependymoma to radiation. Oncotarget 2011;2: 984- 96.
31. Hunt CR, Gupta A, Horikoshi N, Panditsa TK. Does PTEN loss impair DNA double-strand break repair by homologous recombination? Clin Cancer Res 2012;18:920-2.
32. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011;30:3222-33.
33. She Q-B, Chandarlapaty S, Ye Q, Lobo J, Haskell KM, Leander KR, et al. Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS One 2008;3:e3065.
34. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Annal Oncol 2010;21:255-62.
35. Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, et al. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res 2011;71:4944-54.
36. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A, et al. Bortezomib-induced "BRCAness" sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011;118:6368-79.
37. Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 2011;19: 664-78.
38. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, et al. Phase 0 clinical trial of the poly (ADP-Ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 2009;27:2705-11.
39. Barros-Silva JD, Leitao D, Afonso L, Vieira J, Dinis-Ribeiro M, Fragoso M, et al. Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients. Br J Cancer 2009;100:487-93.
40. Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, et al. HER-2 Is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. Journal of Clinical Oncology 2006;24:2376-85.
41. Smith V, Hobbs S, Court W, Eccles S, Workman P, Kelland LR. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin. Anticancer Res 2002;22:1993-9.
42. Nguyen D, Zajac-Kaye M, Rubinstein L, Voeller D, Tomaszewski JE, Kummar S, et al. Poly(ADP-ribose) polymerase inhibition enhances p53-dependent and -independent DNA damage responses induced by DNA damaging agent. Cell Cycle 2011;10:4074-82.
43. Cardoso F, Durbecq V, Laes J-F, Badran B, Lagneaux L, Bex F, et al. Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2 positive breast cancer cells in a synergistic manner. Mol Cancer Ther 2006;5:3042-51.
44. Hinz M, Stilmann M, Arslan SC, Khanna KK, Dittmar G, Scheidereit C.A cytoplasmic ATM-TRAF6-cIAP1 module links nuclear DNA damage signaling to ubiquitin-mediated NF-kappaB activation. Mol Cell 2010;40:63-74.
45. Hadian K, Krappmann D. Signals from the nucleus: activation of NFkappaB by cytosolic ATM in the DNA damage response. Sci Signal 2011;4:pe2.
46. Mendeleyev J, Kirsten E, Hakam A, Buki KG, Kun E. Potential chemotherapeutic activity of 4-iodo-3-nitrobenzamide: metabolic reduction to the 3-nitroso derivative and induction of cell death in tumor cells in culture. Biochem Pharmacol 1995;50:705-14.